Time dependent variables were created for viral load and initiation of HCV-related treatment. Other potential risk factors include age, gender, race, ethnicity and viral genotype. Results: 128, 769 patients out of 360, 857 unique patients registered in the VHA HCV CCR database met all of the study inclusion criteria. The median length of follow-up IWR-1 in vivo was 6. 1 years
[SE=3. 0]. Only 24. 3% of study patients initiated treatment and among treated patients, only16. 4% achieved an undetectable viral load at some point after starting treatment. Achieving undetectable viral load was associated with a reduced risk of composite events [adjusted HR=0.73; 95% CI=0.66-0.82] and death [adjusted HR=0.55; 95% CI=0.47-0.64]. Patients with genotype 2 are consistently at lower risk for death [adjusted HR=0.80; 95% CI=0.76-0.84] or the composite clinical endpoint [adjusted HR=0.77; 95% CI=0.74-0.80] relative to the more common
genotype 1. Patients with genotype 3 are consistently Selleck AZD1208 at higher risk for the composite endpoint [adjusted HR=1. 11; 95% CI=1. 07-1. 16] and death [HR=1. 17; 95% Cl: 1. 11-1. 24] relative to patients with genotype 1. Age, male gender and white race were consistent predictors of increased risk for liver events and death. Conclusions: Treatment-induced viral load reduction, genotype and several demographic factors were found to be significantly associated with both long-term morbidity and mortality for CHC patients treated in the し. S. Veterans Health Administration. Our results use a large, real-world sample of HCV patients to verify earlier findings that viral load reduction through treatment can significantly reduce the risk of adverse patient outcomes in HCV patients. Disclosures: Jeffrey McCombs – Consulting: BMS; Grant/Research Support:
BMS Tara Matsuda – Grant/Research Support: BMS Sammy Saab – Advisory Committees or Review Panels: BMS, Gilead, Merck, Vertex, Genentech; Grant/Research Support: Merck, Gilead; Speaking and Teaching: BMS, Gilead, Merck, Vertex, Genentech, Salix, Onyx, Bayer, Kadman; Stock Shareholder: selleck chemicals Salix, Johnson and Johnson Patricia Hines – Employment: Bristol-Myers Squibb Timothy Juday – Employment: Bristol-Myers Squibb; Stock Shareholder: BristolMyers Squibb Yong Yuan – Employment: Bristol Myers Squibb Company The following people have nothing to disclose: Ivy Tonnu-Mihara, Gil L’ Italian “
“See article in J. Gastroenterol. Hepatol. 2010; 25: 1855–1860. Defining a disease or syndrome by what it is not seems, at first inspection, to be not particularly useful in terms of determining a strategy to assist the sufferer.